EMERYVILLE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq:GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors has granted three employees nonqualified stock options to purchase an aggregate of 29,200 shares of its common stock with an exercise price of $2.68, which is equal to the closing price of Gritstone’s common stock on July 15, 2022, the last trading day preceding the grant date of the awards. These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
Read more at globenewswire.comGritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here